Editing Treatment Options (section)

== What Clinical Trials Are Available in 2025? ==

[https://mesothelioma.net/clinical-trials-for-mesothelioma-treatment-what-to-expect/ Clinical trials] offer access to cutting-edge treatments not yet FDA approved, with over 70 actively recruiting trials in the United States as of 2025.

=== What Are the Most Promising Current Trials? ===

'''CAR-T Cell Therapy:''' The TNhYP218 trial at the National Cancer Institute targets mesothelin-expressing tumors, with early results showing 20% significant tumor reduction and 83% 1-year survival in select patients.

'''First AI-Designed Drug:''' ISM6331, developed by Insilico Medicine, became the first AI-designed drug to enter mesothelioma clinical trials with the first patient dosed in January 2025.

'''Liquid Biopsy Breakthrough:''' Johns Hopkins' Phase 2 trial demonstrated that patients with undetectable circulating tumor DNA at cycle 3 had median progression-free survival of 19.84 versus 1.41 months—a 14-fold difference enabling real-time treatment monitoring.

{| style="width:100%; background:#fff3cd; border:1px solid #ffc107; border-left:5px solid #ffc107; border-radius:4px; margin:1em 0;"
|-
| style="padding:15px; color:#856404;" | '''⚠️ Trial Participation Gap:''' Despite 70+ available trials, only 8% of mesothelioma patients participate. Geographic concentration of expertise requires many patients to travel, though patient advocacy organizations provide free trial matching and travel support.
|}

'''Trial Financial Structure:'''

Research costs (study drug, protocol-required tests): Covered by sponsor

Routine care costs: Covered by insurance (ACA mandate)

Travel and lodging: Patient responsibility (assistance programs available)

----